In addition, BRAF V600E mutation has also been identified to a lesser extent in epithelioid GBM[25], ganglioglioma and pilocytic astrocytoma, predominantly in extra-cerebellar location [9], expanding the diagnostic repertoire use of BRAF V600E mutation-specific IHC testing among primary CNS tumors and potentially the identification of tumors suitable for BRAF V600E mutation-targeted therapy. Here, BRAF is linked to central nervous system neoplasm.